Critical Illness Neuropathy (CIN) - A Detailed Review

Definition and Nomenclature

Epidemiology

• Up to 70% of critically ill patients with sepsis develop some degree of CIN (Goldman-Cecil Medicine)
• 50% of ICU patients with sepsis and multiple organ failure who are resident for at least 2 weeks show EDX features of axonal polyneuropathy (Bradley & Daroff)
• 25-100% of patients requiring >7 days of ICU care can be shown by neurophysiologic testing to have ICU-acquired weakness (Murray & Nadel)
• On clinical evaluation, about one-third of critically ill patients exhibit detectable weakness
• Affects all ages but is rare in children; males > females
• Patients with SIRS are at particular risk

Pathophysiology

1. Microvascular Injury

• Sepsis and SIRS trigger a cascade that leads to impaired microcirculation and occlusion of the vasa nervorum (the small blood vessels supplying peripheral nerves)
• This results in ischemic axonal injury, particularly at distal nerve segments
• In burn neuropathy (affecting 11% of severe burn patients), occlusion of vasa nervorum or dissemination of neurotoxins - or both - are responsible

2. Neurotoxin Dissemination

• The systemic inflammatory response may release circulating neurotoxins that directly damage axons
• Nitric oxide excess (produced during sepsis) is thought to injure endothelium and peripheral nerves

3. Disuse and Muscle Catabolism

• Prolonged immobility triggers muscle disuse atrophy
• Systemic inflammation sparks active muscle catabolism - compounding weakness independent of nerve injury

4. Hyperglycemia and Metabolic Derangements

• Hyperglycemia is an independent risk factor
• Intensive insulin therapy (glucose 80-110 mg/dL) reduced the incidence of CIN/CIM from 52% to 29% in one landmark study
• The protective mechanism involves reduction of inflammation and decreased nitric oxide levels, protecting vascular endothelium

Risk Factors

Clinical Features

Symptoms

• Generalized flaccid weakness with distal prominence (limbs affected more distally)
• Respiratory muscle weakness - a major cause of failure to wean from mechanical ventilation (excluding cardiac and pulmonary causes, this is the primary reason for weaning difficulty)
• Hyporeflexia or areflexia
• Muscle wasting (absent in up to 1/3 of patients)
• Facial muscles and cranial nerves are typically spared
• Pain and paresthesias are NOT features of classic CIN - their presence should prompt consideration of an alternative diagnosis

What Makes Diagnosis Difficult

• Patients are often encephalopathic or sedated
• Multiple lines, drains, and immobilization impede examination
• CIN and CIM frequently co-exist, making clinical separation difficult
• Weakness is often underappreciated by clinical staff

Electrodiagnostic (EDX) Findings

Nerve Conduction Studies (NCS)

• Reduced CMAP amplitudes (compound muscle action potentials) - primary finding reflecting axonal motor loss
• Reduced SNAP amplitudes (sensory nerve action potentials) - to a lesser extent
• Normal or near-normal conduction velocities - this is key in distinguishing CIN from demyelinating neuropathies like GBS
• The pattern is a distal axonal polyneuropathy

Needle EMG

• Fibrillation potentials - evidence of active denervation
• Positive sharp waves
• Decreased MUAPs (motor unit action potentials)
• Increased action potential duration
• Reduced compound muscle action potentials on motor nerve stimulation with spontaneous electrical activity on needle recording

CSF

• Almost always normal - an important distinguishing feature from Guillain-Barré syndrome

Biopsy (if performed)

• Primary axonal degeneration, more severe distally than proximally
• In the myopathic component: type II muscle fiber atrophy, thick filament (myosin) loss, and occasionally necrotizing myopathy

Distinguishing CIN from Critical Illness Myopathy (CIM)

Distinguishing CIN from Guillain-Barré Syndrome (GBS)

Management

Preventive Strategies (most important)

1. Aggressive early treatment of sepsis and septic shock - reduces incidence of CIN/CIM
2. Glycemic control - target glucose ≤180 mg/dL (current guidelines); early studies showed benefit with tighter control (80-110 mg/dL), but this has been tempered due to hypoglycemia risk
3. Avoid or minimize neuromuscular blocking agents where possible
4. Avoid or minimize corticosteroids where clinically feasible
5. Early mobilization and physical/occupational therapy - even in mechanically ventilated patients, this reduces ventilator duration, delirium, and improves functional independence at discharge
6. Nutritional optimization - correct hypophosphatemia; avoid overfeeding; enteral preferred over early parenteral nutrition

Pharmacologic Adjuncts (emerging evidence)

• Phosphodiesterase (PDE3 and PDE4) inhibitors have been investigated
• Levosimendan (calcium sensitizer) has shown some benefit in preserving diaphragm function
• High-dose IVIG has been described in CIN accompanying SARS-CoV-2 infection (case-based evidence only)

Rehabilitation

• Most survivors require intensive rehabilitation
• Some degree of persistent functional disability is common even in survivors

Prognosis

• Directly dependent on the prognosis of the underlying illness
• In survivors:
  • CIM has a better and more favorable prognosis than CIN
  • Most patients with CIM recover in 3-6 months following ICU discharge
  • CIN recovery may take many months to over a year; some patients retain persistent deficits
  • Most patients experience at least some degree of recovery; ultimate disability is determined by degree of persistent weakness
  • Neurophysiologic abnormalities arise early, accumulate during illness, and usually affect both nerves and muscles

Special Considerations

COVID-19 and CIN

Respiratory Failure

• CIN is a major contributor to ventilator-weaning failure
• Diaphragm weakness occurs due to both CIN (denervation) and ventilator-induced diaphragmatic dysfunction (VIDD)
• Diaphragm atrophy begins within 24-36 hours of controlled mechanical ventilation from disuse

Long-term Outcomes

Key Points Summary

1. CIN is a distal, axonal, length-dependent sensorimotor polyneuropathy - NOT demyelinating
2. Up to 70% of septic ICU patients develop some degree of CIN
3. It is a major cause of weaning failure from mechanical ventilation
4. Pain and paresthesias are absent - their presence suggests another diagnosis
5. CSF is normal - distinguishing from GBS
6. EDX: reduced CMAP + SNAP amplitudes, normal conduction velocity, fibrillations on EMG
7. No specific treatment - prevention through good sepsis care, glycemic control, early mobilization, and avoiding unnecessary NMBAs/steroids
8. Prognosis is better for CIM than CIN; both depend on the underlying illness outcome